ACHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Acadia Healthcare Company Inc (ACHC) is not a strong buy for a beginner, long-term investor at this time. Despite a recent positive earnings report and revenue growth, the company faces significant operational and macroeconomic headwinds, as reflected in its declining net income, negative EPS, and multiple downward revisions of price targets by analysts. Additionally, the stock's overbought RSI and lack of strong trading signals suggest limited immediate upside potential. Holding off on investment until there is clearer evidence of sustained operational improvement and financial stability is recommended.
The technical indicators show mixed signals. The MACD is positive and expanding, indicating bullish momentum, but the RSI is at 93.373, signaling the stock is overbought. Moving averages are converging, suggesting indecision in the trend. The stock recently broke above R1 (21.124) and is approaching R2 (22.769), but the post-market decline (-1.75%) indicates potential resistance near current levels.
Q4 2025 revenue increased by 6.1% YoY, reaching $821.5 million.
Q4 adjusted earnings of $0.07 per share exceeded expectations.
Positive future revenue guidance for 2026, projected between $3.37 billion and $3.45 billion.
Net income dropped significantly to -$1.18 billion, down 3710.36% YoY.
EPS fell to -$13.02, down 3820% YoY.
Analysts have consistently lowered price targets, citing operational and macroeconomic headwinds.
Hedge funds are selling, with a 194.77% increase in selling activity last quarter.
The stock is overbought based on RSI, suggesting potential for a pullback.
In Q4 2025, revenue grew by 6.1% YoY to $821.5 million, indicating operational stability. However, net income plummeted to -$1.18 billion, and EPS dropped to -$13.02, reflecting severe profitability challenges. Gross margin remained flat at 100%.
Analysts have mixed views. While some maintain Buy ratings, most have lowered price targets significantly, citing operational headwinds, increased liability expenses, and limited near-term catalysts. Recent price targets range from $13 to $24, with a general consensus of cautious optimism for long-term recovery but limited short-term upside.
